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PURPOSE: Prognostic schemes that rely on clinical variables to predict outcome after resection of colorectal
metastases remain imperfect. We hypothesized that molecular markers can improve the accuracy of prognostic
schemes. METHODS: We screened the transcriptome of matched colorectal liver metastases (CRCLM) and
primary tumors from 42 patients with unresected CRCLM to identify differentially expressed genes. Among the
differentially expressed genes identified, we looked for associations between expression and time to disease
progression or overall survival. To validate such associations, mRNA levels of the candidate genes were assayed
by qRT-PCR from CRCLM in 56 additional patients who underwent hepatectomy. RESULTS: Seven candidate
genes were selected for validation based on their differential expression between metastases and primary tumors
and a correlation between expression and surgical outcome: lumican; tissue inhibitor metalloproteinase 1; basic
helix-loop-helix domain containing class B2; fibronectin; transmembrane 4 superfamily member 1; mitogen
inducible gene 6 (MIG-6); and serpine 2. In the hepatectomy group, only MIG-6 expression was predictive of poor
survival after hepatectomy. Quantitative PCR of MIG-6 mRNA was performed on 25 additional hepatectomy
patients to determine if MIG-6 expression could substratify patients beyond the clinical risk score. Patients within
defined clinical risk score categories were effectively substratified into distinct groups by relative MIG-6
expression. CONCLUSIONS:MIG-6 expression is inversely associated with survival after hepatectomy and may be
used to improve traditional prognostic schemes that rely on clinicopathologic data such as the Clinical Risk Score.
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epatic resection combined with chemotherapy is the standard
eatment for patients with hepatic colorectal cancer metastases
RCLM) and can lead to a 5-year survival of 30% to 58% [1,2]. The
proved survival compared to chemotherapy alone, where patients
rely survive beyond 5 years, is ascribed to improvements in
erative techniques, perioperative management, better imaging, and
ore effective chemotherapy. Two first-line therapies, 5-fluorouracil-
ucovorin-oxaliplatin and 5-fluorouracil-leucovorin-irinotecan, are
proved for advanced-stage CRCLM [3,4]. However, substantial
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CRCLM.
As surgeons become increasingly aggressive in resecting CRCLM,
equently accepting patients over 80 years old and with more
tensive comorbidities, it becomes increasingly important to use
udent patient selection criteria based on biologic determinants of
tcome. Thus, scoring systems have been developed with the goal of
ratifying patients considered for liver resection into risk groups.
ch prognostic schemes utilize clinicopathologic variables to
timate the risk of recurrence and death after hepatectomy for
RCLM [5–9]. Patients with a low risk of recurrence after
patectomy may not benefit from neoadjuvant or adjuvant
emotherapy and may avoid the toxicity of perioperative chemo-
erapy [10]. However, when the risk of recurrence is high or the
ance of complete resection is in question, delayed hepatectomy
ter a period of neoadjuvant therapy should be considered [11]. A
oadjuvant treatment course provides time to determine whether
ditional disease is present, allows assessment of tumor response to
emotherapy, and may facilitate complete tumor resection in
tients with extensive hepatic metastases [12]. The potential benefits
delayed resection should be weighed against the risk of preoperative
patotoxicity, disease progression, and the higher complication rates
sociated with hepatectomy after neoadjuvant therapies [13].
lthough no clinical feature should absolutely exclude a patient
om potentially curative hepatectomy, nonoperative management
ould be considered in those with an exceedingly high risk of
currence and poor performance status.
The Clinical Risk Score (CRS) is a prognostic scheme composed of
e preoperative variables: tumor number; largest tumor diameter;
mph node status during resection of the primary tumor; disease-free
terval; and serum carcinoembryonic antigen level [5]. These are
ctors prognostic for clinical outcome and are generally available in
e preoperative evaluation of patients. The CRS ranges from 0 to 5,
pending on the number of unfavorable characteristics present. Each
riable in the CRS is equally weighted with a single point for each
favorable characteristic. Ideal candidates for hepatectomy have
litary metastases with a diameter less than 5 cm, serum CEA
arcinoembryonic antigen) b200 ng/ml, metachronous disease, and
gative regional lymph nodes found at resection of the primary
mor (i.e., CRS = 0). However, even the most favorable CRS of 0 is
sociated with a 5-year actuarial survival rate of only 60%. Thus,
tients within the lowest CRS category are still at risk of recurrence
d death.
Although the CRS is a validated prognostic system, it remains
perfect [14]. One investigation of long-term outcomes after
patectomy found that patients with a CRS of 0-2 had a 10-year
tuarial survival rate twice as high as patients with a CRS of 3-5
1% versus 10%) [15]. However, no preoperative clinical feature or
RS precluded a curative outcome in that study. One other study
at attempted external validation of three prognostic schemes for
RCLM, including the CRS, failed to confirm any predictive utility
a cohort of 662 patients [16]. Recently, Dupre et al. reported that
oring systems by themselves are of limited value for stratifying
tients operated on for recurrent colorectal liver metastases [17]. We
ve sought to improve prognostic schemes in order to better guide
inicians in the application of individualized treatment plans and to
termine the best therapeutic course for their patients.
The molecular heterogeneity of colorectal cancer leads to large
riations in the response of individual patients to therapy [18].icrosatellite instability and a small group of molecular markers,
cluding the mutational status of the BRAF and KRAS genes, are
ed for treatment decisions and patient stratification. However,
oups of patients defined by these molecular markers still differ
gnificantly in their responses to therapy. In recent years, several
proaches to further subtype CRC have come into use, and among
e most powerful of these is gene expression profiling, which can
prove on the limitations of single gene testing. Gene expression
ofiling has defined subtypes of colorectal cancers that are predictive
prognostic of patient responses to therapies. [18]
In the present study, we sought to find prognostic markers for
RCLM and to determine if such markers could improve the
curacy of the CRS. We used microarrays to compare the
anscriptome in CRCLM versus their primary tumors. From a
oup of genes with differential expression between CRCLM and
eir primary tumors, we selected a subgroup of genes with expression
vels that associated with survival or time to disease progression. We
lidated the findings by quantitative PCR of mRNA from additional
tients and found one gene, mitogen inducible factor-6 (MIG-6),
hich was predictive of poor survival. Lastly, we tested whetherMIG-
expression could substratify patients within defined CRS categories.
ur results show that molecular subtypes can complement clinical
sk stratification to distinguish lower- from higher-risk patients
ith CRCLM.aterials and Methods
umor Retrieval and RNA Extraction
All institutional review board requirements for human studies were
et, and informed consent was obtained from all patients. All tissues
ere obtained at the time of surgery. All tissues were obtained at the
e of surgery. Resected or Tru-cut needle biopsied (superficial) liver
etastases (0.5-1.0 g) were snap frozen in the operating room within
minutes of harvest by transfer to a Dewar flask containing liquid
trogen, transported to the laboratory, and stored at −80°C.
milarly, samples of resected primary colon or rectal tumors were
ken in the operating room under the observation of a pathologist to
eserve surgical and pathological margins and then snap frozen.
Matched samples of primary colon tumor (T); normal colon (N);
d, in all but 6 cases, metastatic tumors of the liver (M) were
tained from each of 42 patients treated at the University of
alifornia at San Francisco Medical Center. Laser capture microdis-
ction was performed on frozen tissue sections to separate normal
d cancerous epithelial cells from surrounding stromal elements.
NA Extraction
RNA was extracted from tissue lysates using the RNeasy kit
iagen, Inc., Valencia, CA) and amplified using an in vitro
anscription-mediated procedure that maintains relative abundances
mRNAs [19]. Each sample was separately labeled with Cy3 and
y5 fluorescent dyes. Prior to labeling, nonhuman RNA transcripts
rresponding to control clones on microarrays were spiked into each
mple in known amounts. The amounts of the spiked control
anscripts were varied between the Cy3- and Cy5-labelings to create
own differentials in the levels of some of these genes. Cy3- or Cy5-
beled nucleotides were incorporated during first-strand cDNA
nthesis by reverse transcription using SuperScript II (Invitrogen
orp., Carlsbad, CA), primed with (dT)25 and random nonamers
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gestion, the labeled probe was purified using the QIAquick PCR
rification kit (Qiagen, Inc., Valencia, CA).
NA Microarray Assays
DNA microarray analysis was performed as described [20]. mRNA
pression was measured using two-color microarrays containing
fferent sets of cDNA clones. The dsDNA clones were produced by
CR using primers complementary to the vector sequences flanking the
NA inserts. Each slide included approximately 384 human
ousekeeping” genes and non-human (e.g. Arabidopsis thaliana,
rosophila melanogaster, plasmid, etc.) clones for quality control. PCR
oducts were assessed for purity and yield by agarose-gel electropho-
sis and were sequenced to verify their identities. Clones found to
ntain Alu repetitive elements were excluded from further analysis. A
tal of 36,518 clones that passed the quality criteria were assigned to 1
17,708 unique transcripts by GenBank accession number,
presenting 10,671 unique genes by LocusLink ID. Of these, 6501
nes were measured by at least 2 clones, usually with different
quences. After hybridization and washing, slides were scanned with a
eneration III scanner (Molecular Dynamics). Relative gene expression
as measured between pairs of co-hybridized samples. Depending on
hat samples were available from each patient, three comparisons
expression levels were made: metastatic tumor vs. primary tumor
/T), primary tumor vs. normal epithelium (T/N), and metastatic
mor vs. normal epithelium (M/N). In each comparison, the pair of
mples was measured twice with reverse labeling to eliminate bias
troduced by the fluorescence properties of the different dyes. For 32 of
e patients, T/N, M/N and M/T expression were all measured.
icroarray Data Analysis
Microarray image analysis was performed using ImaGene software
ioDiscovery, El Segundo, CA). For each spot, the median pixel
tensity and standard deviation were determined, as well as the spot
ea, signal area, and local background intensity. For each cDNA
one, the results from four spots (two duplicates per slide, Cy3 and
y5 labeled) were averaged, and a standard deviation was calculated.
clone was detected if its signal was at least 5 standard deviations
ove background. A ratio of expression between the two samples and
s uncertainty were calculated from the intensities. Each array was
rmalized such that the median ratio observed among the clones
easuring genes spiked into theCy3 andCy5 samples in equal amounts
as one. A global normalization was then applied such that the median
tio observed across all of the cDNA spots on all of the arrays for each
mple was 1. For each ratio, a significance call was assigned: undetected
n both the numerator and denominator), on (detected in the
merator only), off (detected in the denominator only), up or down
ignificantly over-expressed in the numerator or denominator,
spectively), or equal (detected, but ratio not significantly different
om one). To be called significantly up- (down-) regulated, a gene’s
pression must not only be greater (less) than the cut, but it had to be
eater (less) than 1 with at least 95% certainty based on the uncertainty
the log ratio.
For the 32 patients that had T/N, M/N, and M/T expression
easurements, consistency was required between the results of
e three measurements for each spot, such that 4/5 b (T/N)*(M/T)/
/N) b 5/4, i.e., the three ratios should cancel to give a value of 1
ithin 25%. A list of genes that were differently expressed by more
an 1.5-fold between the metastatic and primary tumors of thesetients was generated. The number of ratios deemed sufficiently well
easured to use (detected; consistent between T/N, M/N, and M/T
easurements) varied for different spots. At least 10 good
easurements were required for each spot to be considered. A total
22,344 of 36,518 spots, assigned to 8027 of the 10,671 unique
nes on the arrays, passed this criterion. Maximum likelihood
timates of the upper and lower 99% confidence limits on the
evalence in the parent population were calculated for each spot on
e basis of the number of ratios exceeding the cut out of the number
good ratios. Spots judged to be up- or downregulated in 20% of the
rent population with 99% certainty were included in the list. Thus,
only 10 good ratios were measured for a particular spot, 7 would
ve to make the cut (70%); if there were 32 good ratios, 14 would
ffice (43%). When more than one spot assigned to a particular gene
et these criteria, their average expression ratio in each patient was
lculated, weighted by the inverse uncertainty squared for each ratio.
T and qRT-PCR
cDNAs were synthesized from 2 μg total RNA using a SuperScript
I first-strand synthesis kit. One microliter of the first cDNA synthesis
ix was dispensed in triplicate and mixed with Taqman Universal PCR
astermix and Taqman Gene Expression Assays in an end-volume of
μl into optical 384-well plates for Taqman RT-PCR. PCR primers
r MIG-6 [Hs00219060_m1], fibronectin 1 (HS00415006_m1),
ssue inhibitor of metalloproteinase-1 [Hs00171558_m1], serine
roteinase inhibitor member 2 [Hs00299953_m1], lumican
s00158940_m1], basic helix-loop-helix domain containing class
2 [Hs00186419], transmembrane 4 superfamily member-1
s00371997], and the TaqMan probe were obtained from Applied
iosystems. Actin-B [Hs99999903_m1] was chosen as an endogenous
rmalization control. The Applied Biosystems ABI Prism 7900 was
ed for qRT-PCR. Samples were incubated at 95°C for 15 minutes,
llowed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. In
ntemplate control replicates of each gene, no false positives were
tected, and all the assays were done in triplicate. Quantitative RT-
CR triplicate runs were repeated on a separate day to confirm
producibility.
tatistical Analysis
We screened the transcriptome for associations between candidate
ne expression and outcomes using linear regression analysis.
ategorical variables were compared by Chi-square tests. Overall
rvival was estimated using the Kaplan-Meier method. Survival curve
timates were compared by the log-rank test. Cox proportional-hazards
gression was performed on independent variables that were added
quentially in a stepwise fashion such that they were entered if P b .05
d removed if P N .10. Statistical calculations were done with
edCalc Version 7.0.1.0 software (Mariakerke, Belgium). Two-sided
values b .05 were considered statistically significant. Where
plicable, the cutoff point for stratifying gene expression groups was
termined using the Maxstat statistical package in R (The R
oundation for Statistical Computing, Version 2.0.0, Vienna, Austria.
BN 3-900051-00-3, URL: http://cran.r-project.org/).esults
andidate Genes Selected from the Screening Microarray
Using a cDNA-based microarray that included 35,518 spots
presenting 10,671 unique genes, we screened the transcriptome for
Table 1. Sixty-Eight Genes with Increased mRNA Expression in Hepatic Metastases Relative to Primary Colon Tumors from the Same Patient
Locus ID Symbol Gene Spots N N1.5× N2× N4× N10× ON CLUST
8991 SELENBP1 selenium binding protein 1 1 30 56.7% 43.3% 23.3% 6.7% 0.0% 3
163732 CITED4 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 1 26 53.8% 38.5% 23.1% 7.7% 0.0% 3
4060 LUM lumican 4 32 62.5% 43.8% 15.6% 0.0% 0.0% 5
5266 PI3 protease inhibitor 3, skin-derived (SKALP) 1 26 53.8% 50.0% 11.5% 3.8% 0.0% 3
27290 SPINK4 serine protease inhibitor, Kazal type 4 1 21 52.4% 28.6% 28.6% 9.5% 0.0% 3
27248 XTP3TPB XTP3-transactivated protein B 1 26 50.0% 34.6% 19.2% 7.7% 0.0% 3
9518 GDF15 growth differentiation factor 15 2 31 51.6% 38.7% 16.1% 3.2% 0.0% 6
374354 FLJ25621 FLJ25621 protein 1 23 52.2% 34.8% 17.4% 4.3% 0.0% 3
2192 FBLN1 fibulin 1 2 15 53.3% 46.7% 6.7% 0.0% 0.0% 5
11167 FSTL1 follistatin-like 1 2 31 61.3% 41.9% 3.2% 0.0% 0.0% 5
4313 MMP2 matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) 2 26 65.4% 34.6% 3.8% 0.0% 0.0% 5
2049 EPHB3 EphB3 1 27 48.1% 33.3% 18.5% 3.7% 0.0% 6
800 CALD1 caldesmon 1 1 28 50.0% 39.3% 10.7% 3.6% 0.0% 5
57535 KIAA1324 maba1 1 27 51.9% 33.3% 7.4% 3.7% 3.7% 3
4535 MTND1 NADH dehydrogenase 1 2 30 63.3% 36.7% 0.0% 0.0% 0.0% 4
1634 DCN decorin 6 32 53.1% 28.1% 15.6% 0.0% 0.0% 5
26073 POLDIP2 polymerase (DNA-directed), delta interacting protein 2 1 27 51.9% 29.6% 14.8% 0.0% 0.0% 3
26047 CNTNAP2 contactin associated protein-like 2 1 21 52.4% 28.6% 4.8% 0.0% 9.5% 4
1513 CTSK cathepsin K (pycnodysostosis) 1 15 53.3% 33.3% 6.7% 0.0% 0.0% 5
131177 FAM3D family with sequence similarity 3, member D 1 29 48.3% 24.1% 13.8% 6.9% 0.0% 3
5786 PTPRA protein tyrosine phosphatase, receptor type, A 1 29 58.6% 34.5% 0.0% 0.0% 0.0% 4
5327 PLAT plasminogen activator, tissue 2 28 60.7% 28.6% 0.0% 0.0% 0.0% 5
10406 WFDC2 WAP four-disulfide core domain 2 1 25 52.0% 24.0% 12.0% 0.0% 0.0% 3
1278 COL1A2 collagen, type I, alpha 2 2 32 43.8% 31.3% 9.4% 3.1% 0.0% 5
132160 FLJ32332 likely ortholog of mouse protein phosphatase 2C eta 1 31 48.4% 32.3% 6.5% 0.0% 0.0% 4
4536 MTND2 NADH dehydrogenase 2 2 31 54.8% 29.0% 3.2% 0.0% 0.0% 4
7433 VIPR1 vasoactive intestinal peptide receptor 1 1 21 57.1% 28.6% 0.0% 0.0% 0.0% 3
4091 MADH6 MAD, mothers against decapentaplegic homolog 6 (Drosophila) 1 28 60.7% 25.0% 0.0% 0.0% 0.0% 4
1277 COL1A1 collagen, type I, alpha 1 1 20 50.0% 30.0% 5.0% 0.0% 0.0% 5
1504 CTRB1 chymotrypsinogen B1 1 30 53.3% 26.7% 3.3% 0.0% 0.0% 4
6741 SSB Sjogren syndrome antigen B (autoantigen La) 1 27 55.6% 25.9% 0.0% 0.0% 0.0% 4
27122 DKK3 dickkopf homolog 3 (Xenopus laevis) 1 20 50.0% 25.0% 5.0% 0.0% 0.0% 5
23469 PHF3 PHD finger protein 3 1 30 60.0% 20.0% 0.0% 0.0% 0.0% 4
5908 RAP1B RAP1B, member of RAS oncogene family 1 30 53.3% 26.7% 0.0% 0.0% 0.0% 4
5295 PIK3R1 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) 1 25 52.0% 24.0% 4.0% 0.0% 0.0% 4
3297 HSF1 heat shock transcription factor 1 1 30 56.7% 23.3% 0.0% 0.0% 0.0% 4
2 A2M alpha-2-macroglobulin 1 30 46.7% 26.7% 6.7% 0.0% 0.0% 5
81558 LOC81558 C/EBP-induced protein 1 29 51.7% 24.1% 3.4% 0.0% 0.0% 4
5801 PTPRR protein tyrosine phosphatase, receptor type, R 1 29 44.8% 31.0% 3.4% 0.0% 0.0% 3
2487 FRZB frizzled-related protein 1 18 55.6% 16.7% 5.6% 0.0% 0.0% 3
6348 CCL3 chemokine (C-C motif) ligand 3 1 27 51.9% 22.2% 3.7% 0.0% 0.0% 4
2006 ELN elastin (supravalvular aortic stenosis, Williams-Beuren syndrome) 1 27 48.1% 29.6% 0.0% 0.0% 0.0% 4
84859 MGC4126 hypothetical protein MGC4126 2 31 45.2% 25.8% 6.5% 0.0% 0.0% 5
4513 MTCO2 cytochrome c oxidase II 3 31 51.6% 22.6% 3.2% 0.0% 0.0% 4
146880 MGC40489 hypothetical protein MGC40489 1 30 46.7% 26.7% 3.3% 0.0% 0.0% 4
83483 PLVAP plasmalemma vesicle associated protein 1 25 48.0% 28.0% 0.0% 0.0% 0.0% 5
6678 SPARC secreted protein, acidic, cysteine-rich (osteonectin) 1 29 44.8% 24.1% 6.9% 0.0% 0.0% 5
132241 LOC132241 hypothetical protein LOC132241 1 29 51.7% 20.7% 3.4% 0.0% 0.0% 4
67122 Nrarp Notch-regulated ankyrin repeat protein 1 28 42.9% 28.6% 3.6% 0.0% 0.0% 3
398 ARHGDIG Rho GDP dissociation inhibitor (GDI) gamma 1 27 44.4% 18.5% 11.1% 0.0% 0.0% 4
51599 LISCH7 liver-specific bHLH-Zip transcription factor 1 30 50.0% 23.3% 0.0% 0.0% 0.0% 4
81788 SNARK likely ortholog of rat SNF1/AMP-activated protein kinase 1 29 51.7% 20.7% 0.0% 0.0% 0.0% 4
57605 PITPNM2 phosphatidylinositol transfer protein, membrane-associated 2 1 29 51.7% 20.7% 0.0% 0.0% 0.0% 4
51332 SPTBN5 spectrin, beta, non-erythrocytic 5 1 25 48.0% 20.0% 4.0% 0.0% 0.0% 4
4541 MTND6 NADH dehydrogenase 6 6 32 43.8% 25.0% 3.1% 0.0% 0.0% 4
56940 DUSP22 dual specificity phosphatase 22 1 27 48.1% 22.2% 0.0% 0.0% 0.0% 5
2580 GAK cyclin G associated kinase 1 27 51.9% 18.5% 0.0% 0.0% 0.0% 4
23432 GPR161 G protein-coupled receptor 161 1 29 48.3% 20.7% 0.0% 0.0% 0.0% 4
583 BBS2 Bardet-Biedl syndrome 2 1 29 48.3% 20.7% 0.0% 0.0% 0.0% 4
2045 EPHA7 EphA7 1 28 46.4% 21.4% 0.0% 0.0% 0.0% 4
3189 HNRPH3 heterogeneous nuclear ribonucleoprotein H3 (2H9) 1 31 48.4% 19.4% 0.0% 0.0% 0.0% 4
1158 CKM creatine kinase, muscle 1 30 46.7% 20.0% 0.0% 0.0% 0.0% 4
9775 DDX48 DEAD (Asp-Glu-Ala-Asp) box polypeptide 48 1 24 45.8% 20.8% 0.0% 0.0% 0.0% 4
10551 AGR2 anterior gradient 2 homolog (Xenopus laevis) 2 29 41.4% 24.1% 0.0% 0.0% 0.0% 3
1999 ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 1 30 43.3% 20.0% 0.0% 0.0% 0.0% 3
27336 HTATSF1 HIV TAT specific factor 1 1 29 44.8% 17.2% 0.0% 0.0% 0.0% 4
7125 TNNC2 troponin C2, fast 1 28 42.9% 14.3% 0.0% 0.0% 0.0% 4
3040 HBA2 hemoglobin, alpha 2 1 27 48.1% 3.7% 0.0% 0.0% 0.0% 5
Each gene is identified by its LocusLink ID, symbol, and name. The “Spots” column indicates the number of spots (cDNA clones) used to measure each gene’s expression. The “N” column shows the
maximum number of patient samples where a particular gene was measured; this number was used in calculating the average percent prevalence across patients. The average prevalence, for cuts of 1.5-, 2-,
4-, and 10- fold increased M/T expression, or cases where the gene was only detected in the metastatic tumor sample (“ON”), is shown as a percentage of the patients where the gene was measured. The
“CLUST” column indicates which of the clusters shown in Figure 1 each gene belongs to. The genes are ordered by the sum of the prevalence values, in decreasing order.
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Table 2. Seventy-Six Genes with Decreased mRNA Expression in Hepatic Metastases Relative to Primary Colon Tumors from the Same Patient
Locus ID Symbol Gene Spots N N1.5× N2× N4× N10× OFF CLUST
12 SERPINA3 serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 2 25 64.0% 60.0% 48.0% 24.0% 0.0% 1
51761 ATP8A2 ATPase, aminophospholipid transporter-like, Class I, type 8A, member 2 1 15 60.0% 53.3% 40.0% 26.7% 0.0% 1
51129 ANGPTL4 angiopoietin-like 4 1 18 66.7% 61.1% 22.2% 5.6% 0.0% 2
348 APOE apolipoprotein E 2 32 59.4% 50.0% 31.3% 6.3% 0.0% 5
5004 ORM1 orosomucoid 1 1 19 57.9% 42.1% 26.3% 15.8% 0.0% 1
3240 HP haptoglobin 7 29 51.7% 41.4% 27.6% 17.2% 0.0% 1
6347 CCL2 chemokine (C-C motif) ligand 2 2 21 71.4% 42.9% 14.3% 4.8% 0.0% 5
27295 PDLIM3 PDZ and LIM domain 3 1 14 64.3% 50.0% 7.1% 0.0% 7.1% 5
213 ALB albumin 1 14 50.0% 35.7% 21.4% 14.3% 0.0% 2
7076 TIMP1 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) 3 31 67.7% 41.9% 6.5% 0.0% 0.0% 6
2335 FN1 fibronectin 1 4 32 56.3% 40.6% 18.8% 0.0% 0.0% 6
710 SERPING1 serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary) 1 26 50.0% 34.6% 26.9% 3.8% 0.0% 5
8553 BHLHB2 basic helix-loop-helix domain containing, class B, 2 1 26 57.7% 53.8% 0.0% 0.0% 0.0% 6
3303 HSPA1A heat shock 70kDa protein 1A 4 31 48.4% 35.5% 22.6% 3.2% 0.0% 3
6373 CXCL11 chemokine (C-X-C motif) ligand 11 1 11 63.6% 18.2% 9.1% 0.0% 18.2% 5
56937 TMEPAI transmembrane, prostate androgen induced RNA 1 25 48.0% 40.0% 16.0% 4.0% 0.0% 6
6035 RNASE1 ribonuclease, RNase A family, 1 (pancreatic) 1 29 55.2% 31.0% 13.8% 6.9% 0.0% 3
2316 FLNA filamin A, alpha (actin binding protein 280) 2 31 51.6% 41.9% 12.9% 0.0% 0.0% 5
768 CA9 carbonic anhydrase IX 1 18 44.4% 33.3% 16.7% 0.0% 11.1% 6
2885 GRB2 growth factor receptor-bound protein 2 1 21 57.1% 33.3% 14.3% 0.0% 0.0% 5
7564 ZNF16 zinc finger protein 16 (KOX 9) 1 27 51.9% 44.4% 7.4% 0.0% 0.0% 6
4070 TACSTD2 tumor-associated calcium signal transducer 2 1 28 50.0% 28.6% 17.9% 7.1% 0.0% 6
7052 TGM2 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) 1 28 57.1% 32.1% 14.3% 0.0% 0.0% 6
4071 TM4SF1 transmembrane 4 superfamily member 1 1 29 51.7% 41.4% 6.9% 3.4% 0.0% 4
10397 NDRG1 N-myc downstream regulated gene 1 1 30 56.7% 40.0% 6.7% 0.0% 0.0% 2
2207 FCER1G Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide 1 21 61.9% 33.3% 4.8% 0.0% 0.0% 5
1152 CKB creatine kinase, brain 3 32 50.0% 31.3% 12.5% 6.3% 0.0% 3
1514 CTSL cathepsin L 4 31 54.8% 29.0% 9.7% 3.2% 0.0% 5
652 BMP4 bone morphogenetic protein 4 1 24 50.0% 37.5% 8.3% 0.0% 0.0% 6
633 BGN biglycan 1 24 58.3% 37.5% 0.0% 0.0% 0.0% 1
3936 LCP1 lymphocyte cytosolic protein 1 (L-plastin) 1 23 47.8% 26.1% 13.0% 8.7% 0.0% 5
2878 GPX3 glutathione peroxidase 3 (plasma) 1 18 55.6% 33.3% 5.6% 0.0% 0.0% 1
7422 VEGF vascular endothelial growth factor 2 30 53.3% 33.3% 6.7% 0.0% 0.0% 2
4256 MGP matrix Gla protein 1 30 46.7% 36.7% 10.0% 0.0% 0.0% 1
374 AREG amphiregulin (schwannoma-derived growth factor) 1 29 44.8% 27.6% 13.8% 6.9% 0.0% 4
7701 ZNF142 zinc finger protein 142 (clone pHZ-49) 1 28 46.4% 32.1% 14.3% 0.0% 0.0% 3
51366 DD5 progestin induced protein 1 27 44.4% 37.0% 11.1% 0.0% 0.0% 6
10457 GPNMB glycoprotein (transmembrane) nmb 1 26 50.0% 30.8% 11.5% 0.0% 0.0% 5
22822 PHLDA1 pleckstrin homology-like domain, family A, member 1 1 24 50.0% 33.3% 8.3% 0.0% 0.0% 6
10123 ARL7 ADP-ribosylation factor-like 7 3 32 46.9% 31.3% 6.3% 6.3% 0.0% 6
4316 MMP7 matrix metalloproteinase 7 (matrilysin, uterine) 6 32 46.9% 31.3% 9.4% 3.1% 0.0% 6
3576 IL8 interleukin 8 1 21 47.6% 33.3% 4.8% 4.8% 0.0% 6
5163 PDK1 pyruvate dehydrogenase kinase, isoenzyme 1 1 29 58.6% 31.0% 0.0% 0.0% 0.0% 2
1649 DDIT3 DNA-damage-inducible transcript 3 1 28 46.4% 35.7% 7.1% 0.0% 0.0% 2
7033 TFF3 trefoil factor 3 (intestinal) 1 27 44.4% 22.2% 14.8% 3.7% 3.7% 3
4493 MT1E metallothionein 1E (functional) 1 26 46.2% 30.8% 11.5% 0.0% 0.0% 3
7481 WNT11 wingless-type MMTV integration site family, member 11 1 17 52.9% 23.5% 5.9% 0.0% 5.9% 4
10381 TUBB4 tubulin, beta, 4 1 15 60.0% 26.7% 0.0% 0.0% 0.0% 1
5270 SERPINE2 serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 1 28 46.4% 32.1% 3.6% 3.6% 0.0% 6
9590 AKAP12 A kinase (PRKA) anchor protein (gravin) 12 1 20 50.0% 25.0% 5.0% 5.0% 0.0% 2
54206 MIG-6 mitogen-inducible gene 6 1 31 45.2% 35.5% 3.2% 0.0% 0.0% 2
11067 C10orf10 chromosome 10 open reading frame 10 1 24 62.5% 20.8% 0.0% 0.0% 0.0% 6
2159 F10 coagulation factor X 1 18 50.0% 33.3% 0.0% 0.0% 0.0% 4
57561 ARRDC3 arrestin domain containing 3 3 27 59.3% 22.2% 0.0% 0.0% 0.0% 6
4495 MT1G metallothionein 1G 1 27 44.4% 22.2% 11.1% 3.7% 0.0% 3
10628 TXNIP thioredoxin interacting protein 5 32 46.9% 31.3% 3.1% 0.0% 0.0% 3
3939 LDHA lactate dehydrogenase A 2 32 53.1% 25.0% 3.1% 0.0% 0.0% 6
6890 TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 1 24 45.8% 20.8% 8.3% 4.2% 0.0% 3
1942 EFNA1 ephrin-A1 1 28 46.4% 32.1% 0.0% 0.0% 0.0% 4
136 ADORA2B adenosine A2b receptor 1 22 50.0% 27.3% 0.0% 0.0% 0.0% 3
11145 HRASLS3 HRAS-like suppressor 3 1 26 46.2% 30.8% 0.0% 0.0% 0.0% 6
84951 CTEN C-terminal tensin-like 1 21 52.4% 19.0% 4.8% 0.0% 0.0% 6
90637 LOC90637 hypothetical protein LOC90637 1 29 44.8% 27.6% 3.4% 0.0% 0.0% 2
7045 TGFBI transforming growth factor, beta-induced, 68kDa 1 24 50.0% 25.0% 0.0% 0.0% 0.0% 6
5230 PGK1 phosphoglycerate kinase 1 1 32 46.9% 25.0% 3.1% 0.0% 0.0% 6
64065 PERP PERP, TP53 apoptosis effector 1 28 46.4% 17.9% 3.6% 3.6% 0.0% 6
9531 BAG3 BCL2-associated athanogene 3 1 28 42.9% 25.0% 3.6% 0.0% 0.0% 2
23023 KIAA0779 KIAA0779 protein 1 21 47.6% 23.8% 0.0% 0.0% 0.0% 3
567 B2M beta-2-microglobulin 1 28 46.4% 17.9% 0.0% 0.0% 0.0% 3
2317 FLNB filamin B, beta (actin binding protein 278) 1 28 42.9% 14.3% 7.1% 0.0% 0.0% 3
665 BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like 2 30 46.7% 16.7% 0.0% 0.0% 0.0% 2
7431 VIM vimentin 1 28 42.9% 14.3% 3.6% 0.0% 0.0% 5
91452 ACBD5 acyl-Coenzyme A binding domain containing 5 1 27 44.4% 14.8% 0.0% 0.0% 0.0% 4
1508 CTSB cathepsin B 1 31 48.4% 9.7% 0.0% 0.0% 0.0% 6
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Table 2. (continued)
Locus ID Symbol Gene Spots N N1.5× N2× N4× N10× OFF CLUST
55818 JMJD1 jumonji domain containing 1 1 28 42.9% 14.3% 0.0% 0.0% 0.0% 6
5763 PTMS parathymosin 1 31 41.9% 12.9% 0.0% 0.0% 0.0% 3
The columns are the same as in Table 1, except that the prevalence columns indicate percentage of patients exhibiting downregulation and the “OFF” column indicates the percentage of patients where
expression was detected in the primary tumor but not the metastasis.
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lorectal cancer relative to their primary tumors in 42 patients. The
aracteristics of these patients were: median age 59 years (range 31-
); 61% male, 29% female; primary tumor site 43% right colon,
% left colon, 2% right and left colon, 22% rectum; primary node
atus 15% positive, 85% negative; time to progression 91% b/= 12
onths (synchronous) and 9% N12 months (metachronous); the
edian number of hepatic metastases was 3 with a range of 1-11; and
e average CEA was 141.
In the screen, 22,344 spots representing 8,027 unique genes met
iteria for analysis. From the 10,671 genes in the microarray, 144
monstrated differential expression between primary colon tumors
d matched hepatic metastases. Differential expression was defined
at least 1.5-fold difference in at least 20% of matched primary and
etastatic samples. Transcripts showing a tendency for increased
pression in the metastases relative to primary tumors are in Table 1,
hile those exhibiting decreased expression are in Table 2.
ierarchical clustering applying the Pearson correlation for the
stance metric and complete linkage identified six distinct spot
usters, which are shown in the heat map of differentially expressed
nes (Figure 1).
We found 68 genes that were consistently up-regulated and 76 that
ere down-regulated in CRCLM relative to matched primary tumors.32
 P
a
tie
n
ts
1 2 3 4
gure 1. Expression of genes that show significant up- or downregu
mors from the same patient in 20% or more of the patient popul
pregulation is indicated by shades of red, downregulation is indicated
tios that failed to pass detection or consistency criteria. Tables 1 andom this group of 144 differentially expressed genes, 7 were selected
r validation based on the association between mRNA level (using
lues obtained from the microarray) and clinical outcome (Table 3):
mican, a proteoglycan of the extracellular matrix reported to be
erexpressed in colorectal breast, neuroendocrine, and other cancers
1]; tissue inhibitor of metalloproteinase 1 (TIMP1), an inhibitor of
atrix metalloproteinases and modulator of other diverse processes in
ncer cells [22]; basic helix-loop-helix domain containing B2
HLHB2), a transcription factor that is induced by hypoxia within
mors [23]; fibronectin, an abundant extracellular matrix protein that
ntributes to altered stromal remodeling during tumorigenesis [24];
M4SF1 (transmembrane 4 superfamily member 1), a tumor-
sociated antigen that regulates cancer cell motility and invasion
5]; serpine2, an extracellular serine protease that is overexpressed in
ncreatic, colon, and stomach cancers that may facilitate invasive
ocesses [26]; andMIG-6, a putative tumor suppressor that negatively
gulates the ErbB family of receptor tyrosine kinases [27,28].
ssociation of Candidate Genes in CRC Metastases with
linical Outcome
To determine whether the expression of the candidate genes
entified above as correlating with clinical outcome for unresectable
tients with colorectal metastases confined to the liver also applied toPearson distance
complete linkage
5 6
lation in metastatic tumors of the liver relative to primary colon
ation with 99% certainty based on a sampling of 32 patients.
by shades of green, black indicates no change, and gray indicates
2 indicate which cluster each of the genes belongs to.
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Table 3. Seven Candidate Genes Were Selected on the Basis of Differential Expression Between
Colorectal Liver Metastases and Their Corresponding Primary Tumor and an Association Between
mRNA Level (as Determined by the Microarray Analysis) and Clinical Outcome (Pb.05)
Candidate Gene Name Relative Expression
in CRCLM
Clinical Variable
LUM Lumican Higher OS
TIMP1 Tissue inhibitor of
metalloproteinase 1
Lower TTP
TS
BHLHB2 Basic helix-loop-helix domain
containing, class B, 2
Lower OS
FN1 Fibronectin Lower TTP
TM4SF1 Transmembrane 4
superfamily member 1
Lower OS
MIG-6 Mitogen-inducible gene 6 Lower TTP
SER2 Serpine2 Lower OS
TS
OS, overall survival; TTP, time to progression of liver metastases.
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556 MIG-6 in Colon Cancer Donner et al. Translational Oncology Vol. 12, No. 3, 2019tients undergoing potentially curative hepatectomy for CRCLM,
e performed qRT-PCR of the 7 candidate genes on CRCLM from
additional patients. qRT-PCR allowed us to more accurately
antify the levels of each transcript than obtaining such information
om an array and therefore allowed more accurate substratification of
tients into MIG-6–high and MIG-6–low groups. Since we often
d not have matching primary tumors for these patients, mRNA
vels of the metastasis and normal tissue were compared. The
seline clinical variables and their association with overall survival of
e group of 56 patients who underwent potentially curativeble 4. Results of Univariate Association of Clinicopathologic Variables with Overall Survival
riable n Median Survival (Months)
e 26 68
b60
≥60 30 36
x
Female 18 37
Male 38 32
ate of hepatectomy
After January 1, 2000 19 29
Before January 1, 2000 37 40
imary tumor site
Colon 47 36
Rectum 9 51
isease-free interval
Metachronous 23 54
Synchronous 33 33
epatic lobe involvement
Unilobar 40 36
Bilobar 16 36
imary tumor node status
N0 14 43
N1 41 36
eoperative CEA
b200 ng/ml 39 33
≥200 ng/ml 6 65
iameter of largest met
b5.0 cm 28 58
≥5.0 cm 28 30
umber of metastases
Solitary 27 54
Multiple 29 29
epatectomy EBL
b1000 ml 30 36
≥1000 ml 25 33
epatectomy margin
b1.0 cm 27 40
≥1.0 cm 29 31
eoperative CEA level was not obtained in 13 patients. Primary tumor nodal status was unknown in twpatectomy are in Table 4. The median follow-up time of the
rviving patients in this group was 97 months after hepatectomy
ange 55-107 months).
To determine if expression of any of the seven genes was associated
ith survival after hepatectomy, we dichotomized patients into high-
d low-expression groups according to the median relative mRNA
vel. In this analysis,MIG-6 was the only gene whose expression was
edictive of survival (Table 5). Patients in the lower 50th percentile
MIG-6 expression had a median survival that was over twice as
ng as that of patients in the upper 50th percentile (P = .01, Table 5).
sing Maxstat software to optimize the cutoff value for high and low
IG-6 expression, a statistically significant difference in overall
rvival was found by Kaplan-Meier analysis (log-rank P = .0024,
igure 2). This approach also showed that none of the candidate
nes, including MIG-6, was predictive of liver disease–free survival
DFS) (Table 5).
igh- and Low-CRS Patients Further Stratified by MIG-6
ene Expression
Because MIG-6 was the only gene whose expression predicted
rvival, we were interested in whether patients with a high or low
RS could be further stratified by MIG-6 expression. This led us to
rform qRT-PCR of MIG-6 mRNA on 25 additional patients with
RCLM (total n = 81 patients). To determine if the CRS predicted
rvival after hepatectomy in this cohort, we generated Kaplan-Meier
rvival estimates of low CRS (0-2) and high CRS (3-5). AlthoughHazard Ratio 95% CI P Value
0.63 0.33-1.18 .15
0.88 0.46-1.70 .71
1.28 0.65-2.71 .44
1.03 0.46-2.34 .94
0.61 0.33-1.17 .14
1.32 0.66-2.58 .44
0.84 0.42-1.69 .63
1.37 0.52-3.44 .55
0.50 0.25-0.91 .03
0.57 0.30-1.05 .07
1.16 0.62-2.19 .64
1.11 0.59-2.08 .74
o patients. CEA, carcinoembryonic antigen; met, metastasis.
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Table 5. Univariate Analysis of Candidate Genes
Candidate Gene Expression n Median Survival (mos) Hazard Ratio (95% CI) P Value Survival Median LDFS
(mos)
Hazard Ratio (95% CI) P Value LDFS
LUM
Low 28 50 0.64 .19 51 0.55 .10
High 27 32 (0.30-1.28) 20 (0.24-1.14)
TIMP1
Low 28 57 0.60 .14 51 0.51 .07
High 28 31 (0.29-1.19) 20 (0.23-1.06)
BHLHB2
Low 28 57 0.59 .13 NR 0.55 .11
High 28 31 (0.28-1.17) 27 (0.26-1.16)
FN1
Low 28 57 0.63 .18 46 0.80 .54
High 28 31 (0.30-1.26) 27 (0.37-1.69)
TM4SF1
Low 28 42 0.90 .77 46 0.94 .86
High 28 31 (0.44-1.83) 27 (0.44-1.99)
Mig-6
Low 28 67 0.42 .01 NR 0.55 .10
High 28 29 (0.18-0.80) 20 (0.24-1.12)
SER2
Low 28 42 0.79 .50 46 0.76 .47
High 27 31 (0.38-1.61) 20 (0.35-1.62)
Quantitative RT-PCR was performed on colorectal liver metastases from 56 additional patients that underwent hepatectomy. Patients above and below the median expression level were compared by log-
rank testing.
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edian survival of the high-CRS group was 25 months. The Kaplan-
eier survival estimates for the low-CRS group were higher than
ose for the high-CRS group (log-rank P = .005, Figure 3). Within
e low-CRS group (n = 40), stratifying by medianMIG-6 expression
sulted in low– (n = 20) and high– (n = 20) MIG-6 expression
bgroups (Figure 4A). Median survival was 33 months for patients in
e subgroup with low CRS and high MIG-6 but was not reached inw
ex
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Gehan:    0.041
MIG6 < 0.63484 (N = 32)
MIG6 > 0.63484 (N = 23)
gure 2. Kaplan-Meier survival estimates of survival in patients
ter resection stratified by MIG-6 expression. MaxStat software
as used to optimize the cutoff value for high and low MIG-6
pression. A statistically significant difference in overall survival
as found by this analysis (log-rank P = .0024)
Fi
M
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hi
.0
w
ta
sue subgroup with low CRS and low MIG-6. When patients in the
w-CRS group were substratified by the median MIG-6 level,
atistically distinct survival curves by log-rank testing (P = .03)
sulted.
When patients in the high-CRS group (n = 41) were stratified by
edian MIG-6 expression, the median survival was almost twice as
ng in the low–MIG-6 subgroup (n = 21) as it was in the high–MIG-
subgroup (n =20) (Figure 4B). As with the low-CRS group, patients
ith a high CRS could be effectively substratified by median MIG-6
pression, resulting in statistically distinct survival curves by log-rank
sting (P = .04).gure 3. Patient stratification for overall survival by CRS. Kaplan-
eier survival estimates comparing low-CRS (0-2) vs. high-CRS
–5) groups. The median overall survival was 25 months in the
gh-CRS group, but it was not reached in the low-CRS group (P =
05). Fourteen patients did not have preoperative CEA levels and
ere excluded from the analysis. Numbers below the figure are life
bles designating how many patients are represented in the
rvival curves.
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Figure 4. MIG-6 can substratify patients beyond the CRS. Patients
divided into low-CRS (0-2) and high-CRS (3-5) groups were further
stratified by median MIG-6 expression. (A) Within the low-CRS
group, patients were separated into two groups: those in the upper
50th percentile of MIG-6 expression and those in the lower 50th
percentile. The median overall survival was 33 months in the
upper–MIG-6 subgroup and was not reached in the lower–MIG-6
group (P = .03). (B) Similarly, within the high-CRS group, patients
were separated into two groups: those in the upper 50th percentile
of MIG-6 expression and those in the lower 50th percentile. The
median overall survival in the upper– and lower–MIG-6 subgroups
was 18 and 33 months, respectively (P = .04). Numbers below the
figure are life tables designating how many patients are represent-
ed in the survival curves.
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e used gene expression profiling to identify differentially expressed
nes in CRCLM relative to matched primary tumors. Among the
nes identified, MIG-6 (also called gene-33, RALT, or ERRFI1)
codes an adaptor protein that interacts with and inhibits the
tivities of members of the ErbB receptor family and other receptor
rosine kinases [29,30]. The human MIG-6 gene is on chromosome
36, a locus associated with many cancers [31], and MIG-6 is
oposed to be a tumor suppressor [28,32]. Consistent with this,
IG-6 expression is reduced in human breast, skin, pancreatic, and
arian cancers, and diminished MIG-6 expression in patients with
east cancer correlates with poor survival [33,34]. Furthermore,
rmline disruption of the murineMIG-6 gene leads to cancers of the
ng, gallbladder, bile duct, skin, and gastrointestinal tract [29,32].
entification ofMIG-6 as a gene that has low expression in CRCLM
lative to matched primary cancers may suggest that MIG-6 can act
a suppressor of metastasis.We found that elevated MIG-6 mRNA expression was associated
ith decreased survival after hepatectomy of CRCLM. This
servation should be considered in concert with results showing
at MIG-6 has diverse functions in both physiology and pathology
hich, depending on context, can promote survival or cell death.
MIG-6 transcription is induced by diverse stimuli including
owth factors [35,36], hormones [37], cytokines [29,38], and
poxia [39]. MIG-6 is a feedback inhibitor of all members of the
rbB receptor family [29,30], with the EGFR being best investigated.
ctivation of the EGFR increases MIG-6 transcription in a RAS-
RK–dependent fashion [40,41], leading to accumulation of the
IG-6 protein within 60-90 minutes. In turn, MIG-6 binds the
rosine kinase domain of the activated EGFR, inactivates the
ceptor tyrosine kinase, and thereby attenuates EGFR action. Thus,
IG-6 −/− mice display epidermal hyperplasia and have an increased
sceptibility to skin carcinogenesis, which is caused by unabated
GFR signaling [29]. During lung development and vascularization,
e absence ofMIG-6 leads to hyperplasia of several tissues, as well as
enhanced apoptosis of endothelial cells and diminished expression
angiogenic factors [42]. Considered together, the observations
mmarized above show that that MIG-6 may coordinate life and
ath decision making to facilitate tissue homeostasis [27,28].
It has been commonly assumed that MIG-6 functions solely as a
mor suppressor and that EGFR acts in an oncogenic manner.
owever, several studies have established the ability of EGFR to
duce apoptosis in breast cancer cells [43–47], while others have
tablished the ability of MIG-6 to protect human breast cancer cells
om apoptosis [42,48]. A strong basis exists for believing that
balanced expression of MIG-6 relative to the EGFR activates
ternalized EGFR, where it may initiate apoptosis [43,44,46,47,49].
ecent studies show that phosphorylation of MIG-6 may negatively
fect its interaction with the EGFR as well as its capacity to induce
afficking of the EGFR [30,50,51]. Since the activity of MIG-6 on
GFR is dependent on its phosphorylation status, localization, and
otein levels, it may be necessary to interrogate these attributes of
IG-6 in patients to know its true prognostic significance.
Petroda et al. [52] recently showed that the identification of
olecular subtypes of colorectal metastases across individual patients
n complement clinical risk stratification to distinguish low-,
termediate-, and high-risk patients with distinct 10-year survivals.
he present study builds on this approach by showing that CRCLM
tients could be stratified within their respective CRS group by
lative MIG-6 expression to improve prognostic accuracy for
tients. Our observations should encourage evaluation of patient
tcomes when MIG-6 expression and MIG-6 expression relative to
GFR localization and abundance are considered in a larger,
ospective study.
This study had several limitations. The patients whose tumor
ecimens were used in the screening array had unresected CRCLM,
hereas patients in the validation group underwent hepatectomy.
eally, screening and validation groups have identical clinical features
d undergo identical treatment. Furthermore, the samples utilized
ere not randomly selected but rather represented patients who had
ssue available for research. We defined high and low MIG-6
pression by retrospectively selecting the most significant cutoff by
g-rank testing. We also used the median expression of MIG-6 to
chotomize patients as a relatively unbiased means of stratifying
yond the CRS. We acknowledge that reaching conclusions using
t points from maximally selected statistics and multiple hypothesis
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sociation betweenMIG-6 expression and survival after hepatectomy
quires larger and perhaps prospective studies.
Despite these limitations, many of which are inevitable in research
ith human tumor specimens, we believe that our central conclusions
e of interest: highMIG-6 expression is a negative prognostic feature
CRCLM; furthermore, determination of MIG-6 expression can
gment the accuracy of prognostic schemes that rely on clinico-
thologic data.
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